Results 51 to 60 of about 27,341 (230)

Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.

The Lancet Gastroenterology and Hepatology, 2020
BACKGROUND An increasing percentage of potential organ donors are infected with hepatitis C virus (HCV). After transplantation from an infected donor, establishment of HCV infection in uninfected recipients is near-universal, with the requirement for ...
J. Feld, M. Cypel, Deepali Kumar, H. Dahari, R. V. Pinto Ribeiro, N. Marks, N. Kamkar, I. Bahinskaya, F. Onofrio, M. Zahoor, Orlando Cerrochi, K. Tinckam, S. Kim, J. Schiff, T. Reichman, M. McDonald, C. Alba, T. Waddell, G. Sapisochin, M. Selzner, S. Keshavjee, H. Janssen, B. Hansen, L. Singer, A. Humar   +24 more
semanticscholar   +1 more source

Distinctive Gut Microbiota in Patients with Overweight and Obesity with Dyslipidemia and its Responses to Long-term Orlistat and Ezetimibe Intervention: A Randomized Controlled Open-label Trial

Frontiers in Pharmacology, 2021
This study investigated the gut microbiota and short chain fatty acids (SCFAs) characteristics of subjects with obesity from Xinjiang in northwestern China, a region with a multiethnic culture and characteristic lifestyle, and to explore the potential ...
Jin Jin, R. Cheng, Yan Ren, Xi Shen, Jiani Wang, Yigui Xue, Huimin Zhang, Xiuhua Jia, Tingting Li, F. He, H. Tian   +10 more
semanticscholar   +1 more source

Ezetimibe: Use, costs, and adverse events in Australia

, 2017
Aim: To analyze the subsidized use and reported adverse events of ezetimibe, used to lower cholesterol, in Australia over the 11 years following its inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2004.
Martin, JH, Tett, SE, Ostini, R, Hollingworth, SA, David, MC   +4 more
core   +1 more source

The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatins⃞

Journal of Lipid Research, 2007
The combination of ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein (NPC1L1), and an HMG-CoA reductase inhibitor decreases cholesterol absorption and synthesis.
Dawn E. Telford, Brian G. Sutherland, Jane Y. Edwards, Joseph D. Andrews, P. Hugh R. Barrett, Murray W. Huff   +5 more
doaj   +1 more source

Ezetimibe promotes CYP7A1 and modulates PPARs as a compensatory mechanism in LDL receptor-deficient hamsters

Lipids in Health and Disease, 2020
Background The LDL-C lowering effect of ezetimibe has been attributed primarily to increased catabolism of LDL-C via up-regulation of LDL receptor (LDLR) and decreased cholesterol absorption.
Bin Xia, Ping Lin, Yubin Ji, Jiayu Yin, Jin Wang, Xiaoqian Yang, Ting Li, Zixun Yang, Fahui Li, Shoudong Guo   +9 more
doaj   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity-Matched Cohort Study. [PDF]

Clin Pharmacol Ther
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Nardi Agmon I, Gurevitz C, Shochat T, Kushnir S, Witberg G, Levi A, Gilon D, Kornowski R, Thavendiranathan P, Abdel Qadir H, Iakobishvili Z.   +10 more
europepmc   +2 more sources

Safety and Effectiveness of High‐Intensity Statins Versus Low/Moderate‐Intensity Statins Plus Ezetimibe in Patients With Atherosclerotic Cardiovascular Disease for Reaching LDL‐C Goals: A Systematic Review and Meta‐Analysis

Clinical Cardiology
It remains controversial whether adding ezetimibe to low/moderate‐intensity statins has a more beneficial impact on the treatment efficacy and safety of patients with existing atherosclerotic cardiovascular disease (ASCVD) compared to high‐intensity ...
H. Soleimani, Asma Mousavi, Shayan Shojaei, Kiarash Tavakoli, D. Salabat, Farid Farahani Rad, Mani K Askari, John Nelson, Mohammad Ruzieh, Kaveh Hosseini   +9 more
semanticscholar   +1 more source

Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9[S]

Journal of Lipid Research, 2011
Reducing circulating LDL-cholesterol (LDL-c) reduces the risk of cardiovascular disease in people with hypercholesterolemia. Current approaches to reduce circulating LDL-c include statins, which inhibit cholesterol synthesis, and ezetimibe, which blocks ...
Brandon Ason, Samnang Tep, Jr. Harry R. Davis, Yiming Xu, Glen Tetzloff, Beverly Galinski, Ferdie Soriano, Natalya Dubinina, Lei Zhu, Alice Stefanni, Kenny K. Wong, Marija Tadin-Strapps, Steven R. Bartz, Brian Hubbard, Mollie Ranalletta, Alan B. Sachs, W. Michael Flanagan, Alison Strack, Nelly A. Kuklin   +18 more
doaj   +1 more source

Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe

Advances in Therapy, 2021
Although several studies have shown that a simplified cardiovascular drug treatment leads to better treatment adherence, limited and conflicting findings have been reported on the separate or single-pill combination of the now recommended association ...
F. Rea, L. Savaré, G. Corrao, G. Mancia
semanticscholar   +1 more source

Atroposelective Construction of Axially Chiral Tetraarylethenes Via NHC‐Catalyzed Desymmetrization

Advanced Science, EarlyView.
We report the first NHC‐catalyzed atroposelective synthesis of axially chiral TAEs via oxidative desymmetrization of prochiral TAE dialdehydes. This catalytic strategy operates under mild conditions and accommodates a broad range of phenolic and nitrogen nucleophiles, delivering diverse axially chiral TAEs in good yields and up to 99% ee.
Yang‐Ze Zheng, Ting‐Rui Luan, Ming‐Hao Song, Zhaofeng Sun, Chuan‐Jun Lu, Long‐Long Xi, Ren‐Rong Liu   +6 more
wiley   +1 more source